P2-18-2SAFETY AND EFFICACY OF BEVACIZUMAB-CONTAINING CHEMOTHERAPY IN NSCLC PATIENTS WITH BRAIN METASTASES

Abstract Background: Prior to 2012, bevacizumab was contraindicated for patients with brain metastases in Japan due to concerns about cerebral hemorrhage. The package insert changed in 2012 to allow careful administration of bevacizumab; however, we still have insufficient data describing the safety and efficacy of bevacizumab-containing chemotherapy. Because bevacizumab may be effective in the treatment of edema associated with brain metastases and radiation necrosis, it may have additional clinical uses. Methods: We retrospectively evaluated non-small cell lung cancer (NSCLC) patients with brain metastases who had received chemotherapy containing bevacizumab at Chiba Cancer Center between April 2012 and December 2013. Results: Thirty patients were eligible for participation in this study. Of the patients in this study, 15 were men, and 15 were women; patients had a median age of 62.5 years, and all except one had histological adenocarcinoma. Surgery, stereotactic radiosurgery, whole brain radiation, and other therapies were performed in 9, 13, 2, and 1 patients, respectively; 5 patients were not treated. Additionally, 26, 1, 2, and 1 patients received the following chemotherapies: CBDCA + PTX + BEV, CDDP + PEM + BEV, PEM + BEV, or BEV monotherapy, respectively. RECIST classifications of brain metastases were complete response in 2 patients, partial response in 7 patients, stable disease in 11 patients, progressive disease in 1 patients, and NE in 9 patients. Grade 3 adverse events included sensory neuropathy in 1 patient, epileptic seizure in 1 patient, dysbasia in 1 patient, viral encephalitis in 1 patient, febril neutropenia in 1 patient, and subcutaneous abscess of the buttocks in 1 patient. Grade 4 epileptic seizure was occurred in 1 patient. There were no cerebral hemorrhage. Conclusion: Bevacizumab did not increase toxicities in patients with brain metastases and appeared to be effective in the treatment of NSCLC patients with brain metastases.